Vonoprazan (Voquezna) was noninferior to lansoprazole (Prevacid) for healing patients with erosive esophagitis, and was superior for maintaining healing, a randomized trial showed. In a modified ...
This study was conducted as a phase IIIb, large-scale, randomised, multicentre, double-blind, prospective, active-controlled clinical trial. The institutional review board of each participating study ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Phathom Pharmaceuticals’ Voquezna tablets 10 mg and 20 mg to treat erosive esophagitis, or ...
Following the FDA approval of vonoprazan in the treatment of erosive esophagitis, Dr Colin Howden discussed important information about the new therapy. In the wake of the recent FDA approval of ...
The US Food and Drug Administration (FDA) has approved vonoprazan 10 mg and 20 mg tablets (Voquezna, Phathom Pharmaceuticals) for the healing and maintenance of healing of all grades of erosive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results